- Home
- TRMB vs BIIB Comparison
TRMB vs BIIB Comparison
Compare TRMB & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRMB
- BIIB
- Stock Information
- Founded
- TRMB 1978
- BIIB 1978
- Country
- TRMB United States
- BIIB United States
- Employees
- TRMB N/A
- BIIB N/A
- Industry
- TRMB Industrial Machinery/Components
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- TRMB Industrials
- BIIB Health Care
- Exchange
- TRMB Nasdaq
- BIIB Nasdaq
- Market Cap
- TRMB 16.9B
- BIIB 18.8B
- IPO Year
- TRMB 1990
- BIIB 1991
- Fundamental
- Price
- TRMB $71.81
- BIIB $126.69
- Analyst Decision
- TRMB Buy
- BIIB Buy
- Analyst Count
- TRMB 5
- BIIB 27
- Target Price
- TRMB $87.40
- BIIB $187.83
- AVG Volume (30 Days)
- TRMB 1.2M
- BIIB 1.5M
- Earning Date
- TRMB 08-05-2025
- BIIB 07-31-2025
- Dividend Yield
- TRMB N/A
- BIIB N/A
- EPS Growth
- TRMB 538.84
- BIIB 26.39
- EPS
- TRMB 6.14
- BIIB 10.12
- Revenue
- TRMB $3,570,600,000.00
- BIIB $9,816,400,000.00
- Revenue This Year
- TRMB N/A
- BIIB N/A
- Revenue Next Year
- TRMB $7.53
- BIIB N/A
- P/E Ratio
- TRMB $11.68
- BIIB $12.51
- Revenue Growth
- TRMB N/A
- BIIB 1.59
- 52 Week Low
- TRMB $48.65
- BIIB $110.04
- 52 Week High
- TRMB $77.78
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- TRMB 55.49
- BIIB 44.92
- Support Level
- TRMB $71.50
- BIIB $129.61
- Resistance Level
- TRMB $73.16
- BIIB $136.84
- Average True Range (ATR)
- TRMB 1.25
- BIIB 3.08
- MACD
- TRMB -0.30
- BIIB -0.80
- Stochastic Oscillator
- TRMB 51.48
- BIIB 11.21
About TRMB Trimble Inc.
Trimble Inc is a technology solutions provider that enables office and mobile professionals to connect their workflows and asset lifecycles to drive a more productive, sustainable future. The company has three reportable segments: Architects, Engineers, Construction, and Owners (AECO). This segment provides software solutions that sell through a direct channel to customers in the construction industry. Field Systems. This segment provides hardware and associated software solutions that sell through dealer partner channels. Transportation and Logistics (T&L). This segment provides solutions for customers working in long-haul trucking and freight shipping markets.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.